OS Therapies (OSTX) Competitors $3.97 +0.06 (+1.53%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends OSTX vs. FHTX, AVIR, ELDN, URGN, RZLT, CMRX, ATYR, MRSN, HRTX, and FULCShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Foghorn Therapeutics (FHTX), Atea Pharmaceuticals (AVIR), Eledon Pharmaceuticals (ELDN), UroGen Pharma (URGN), Rezolute (RZLT), Chimerix (CMRX), Atyr PHARMA (ATYR), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Foghorn Therapeutics Atea Pharmaceuticals Eledon Pharmaceuticals UroGen Pharma Rezolute Chimerix Atyr PHARMA Mersana Therapeutics Heron Therapeutics Fulcrum Therapeutics Foghorn Therapeutics (NASDAQ:FHTX) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings. Does the media prefer FHTX or OSTX? In the previous week, Foghorn Therapeutics had 19 more articles in the media than OS Therapies. MarketBeat recorded 20 mentions for Foghorn Therapeutics and 1 mentions for OS Therapies. OS Therapies' average media sentiment score of 0.67 beat Foghorn Therapeutics' score of 0.14 indicating that OS Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral OS Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is FHTX or OSTX more profitable? OS Therapies has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-357.53% N/A -30.98% OS Therapies N/A N/A -569.57% Does the MarketBeat Community favor FHTX or OSTX? Foghorn Therapeutics received 35 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 62.30% of users gave Foghorn Therapeutics an outperform vote. CompanyUnderperformOutperformFoghorn TherapeuticsOutperform Votes3862.30% Underperform Votes2337.70% OS TherapiesOutperform Votes3100.00% Underperform VotesNo Votes Do insiders and institutionals have more ownership in FHTX or OSTX? 61.5% of Foghorn Therapeutics shares are held by institutional investors. 9.1% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts prefer FHTX or OSTX? Foghorn Therapeutics currently has a consensus target price of $13.80, indicating a potential upside of 168.48%. OS Therapies has a consensus target price of $8.00, indicating a potential upside of 101.51%. Given Foghorn Therapeutics' higher possible upside, equities analysts clearly believe Foghorn Therapeutics is more favorable than OS Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80OS Therapies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Which has higher valuation & earnings, FHTX or OSTX? OS Therapies has lower revenue, but higher earnings than Foghorn Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$25.52M11.20-$98.43M-$1.92-2.68OS TherapiesN/AN/A-$7.79MN/AN/A SummaryFoghorn Therapeutics beats OS Therapies on 8 of the 14 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$84.32M$6.57B$5.12B$19.18BDividend YieldN/A2.98%4.91%3.59%P/E RatioN/A10.5991.3441.28Price / SalesN/A195.381,116.6317.59Price / CashN/A57.1642.5821.28Price / BookN/A5.104.795.32Net Income-$7.79M$151.51M$120.07M$989.88M7 Day Performance31.46%-2.14%-1.90%-3.56%1 Month Performance113.79%-3.13%11.43%-3.70%1 Year PerformanceN/A11.51%30.59%12.12% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS TherapiesN/A$3.97+1.5%$8.00+101.5%N/A$84.32MN/A0.00N/AGap DownFHTXFoghorn Therapeutics2.8809 of 5 stars$4.97-6.2%$16.00+221.9%-14.0%$276.30M$25.52M-2.63120Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeAVIRAtea Pharmaceuticals3.0689 of 5 stars$3.19+8.9%$6.88+115.7%+5.6%$269.44M$351.37M-1.5370High Trading VolumeELDNEledon Pharmaceuticals2.9252 of 5 stars$4.50+2.7%$16.00+255.6%+196.6%$268.83MN/A-2.3310Positive NewsURGNUroGen Pharma3.8754 of 5 stars$11.43+0.7%$43.70+282.3%-28.4%$268.03M$82.71M-3.60200RZLTRezolute3.1803 of 5 stars$4.62+0.7%$24.13+422.2%+387.8%$267.70MN/A-3.6140CMRXChimerix4.3425 of 5 stars$2.91-1.4%$8.50+192.1%+218.1%$261.73M$320,000.00-3.1472ATYRAtyr PHARMA2.4771 of 5 stars$3.10+1.3%$19.25+521.0%N/A$260.22M$235,000.00-3.2656News CoverageMRSNMersana Therapeutics4.3105 of 5 stars$2.10-2.3%$6.00+185.7%-16.2%$259.41M$36.85M-3.52150Positive NewsHRTXHeron Therapeutics3.9582 of 5 stars$1.68+4.7%$5.67+238.3%-2.5%$254.76M$137.74M-8.89300Analyst DowngradeFULCFulcrum Therapeutics1.7135 of 5 stars$4.41+11.4%$9.33+111.6%-22.6%$237.87M$80.87M-13.68100 Related Companies and Tools Related Companies Foghorn Therapeutics Competitors Atea Pharmaceuticals Competitors Eledon Pharmaceuticals Competitors UroGen Pharma Competitors Rezolute Competitors Chimerix Competitors Atyr PHARMA Competitors Mersana Therapeutics Competitors Heron Therapeutics Competitors Fulcrum Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:OSTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OSTX Stock Alerts